|
|
Volumn 56, Issue 6, 2015, Pages 969-
|
|
Reply: Modifying the poor prognosis associated with 18FFDG-Avid NET with peptide receptor chemo-radionuclide therapy (PRCRT)
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC METAL COMPLEX;
DOTATATE LU 177;
FLUORODEOXYGLUCOSE F 18;
FLUOROURACIL;
KI 67 ANTIGEN;
LUTETIUM 177;
RADIOPHARMACEUTICAL AGENT;
SOMATOSTATIN RECEPTOR;
UNCLASSIFIED DRUG;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CONTROLLED STUDY;
HUMAN;
LETTER;
MAJOR CLINICAL STUDY;
METASTASIS POTENTIAL;
NEUROENDOCRINE TUMOR;
OVERALL SURVIVAL;
PEPTIDE RECEPTOR RADIONUCLIDE CHEMOTHERAPY;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
PROGNOSIS;
PROGNOSTIC ASSESSMENT;
PROGRESSION FREE SURVIVAL;
SCINTIGRAPHY;
SOMATOSTATIN RECEPTOR SCINTIGRAPHY;
DIAGNOSTIC USE;
FEMALE;
INTESTINE TUMOR;
MALE;
PANCREAS TUMOR;
SCINTISCANNING;
STOMACH TUMOR;
FEMALE;
FLUORODEOXYGLUCOSE F18;
HUMANS;
INTESTINAL NEOPLASMS;
MALE;
NEUROENDOCRINE TUMORS;
PANCREATIC NEOPLASMS;
POSITRON-EMISSION TOMOGRAPHY;
STOMACH NEOPLASMS;
|
|
EID: 84930340543
PISSN: 01615505
EISSN: 2159662X
Source Type: Journal
DOI: 10.2967/jnumed.115.158006 Document Type: Letter |
|
Times cited : (1)
|
|
References (5)
|
